C R Bard Inc  

(Public, NYSE:BCR)   Watch this stock  
Find more results for C.R. Bard, Inc.�
179.65
-3.26 (-1.78%)
After Hours: 179.65 0.00 (0.00%)
Feb 8, 4:33PM EST  
NYSE real-time data - Disclaimer
Currency in USD
Range 177.47 - 182.13
52 week 163.81 - 202.47
Open 181.76
Vol / Avg. 796,644.00/584,472.00
Mkt cap 12.97B
P/E 101.25
Div/yield 0.24/0.53
EPS 1.77
Shares 73.89M
Beta 0.67
Inst. own 92%
Apr 21, 2016
Q1 2016 C R Bard Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Apr 14, 2016
C R Bard Inc Annual Shareholders Meeting (Estimated) - 10:00AM EDT - Add to calendar
Jan 28, 2016
Q4 2015 C R Bard Inc Earnings Call - Webcast
Jan 28, 2016
Q4 2015 C R Bard Inc Earnings Release
Jan 12, 2016
C R Bard Inc at JPMorgan Healthcare Conference
Dec 1, 2015
C R Bard Inc at Piper Jaffray Healthcare Conference - Webcast
Nov 17, 2015
C R Bard Inc at Stifel Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin 15.65% 3.96%
Operating margin 19.43% 11.54%
EBITD margin - 25.08%
Return on average assets - -
Return on average equity - -
Employees 13,900 -
CDP Score - -

Address

730 Central Ave
NEW PROVIDENCE, NJ 07974-1139
United States - Map
+1-908-2778000 (Phone)
+1-908-2778412 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

C. R. Bard, Inc. (Bard) and its subsidiaries are engaged in the design, manufacture, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. . The Company reports its sales in four major product group categories: vascular, urology, oncology and surgical specialty. The Company also has a product group of other products. The Company's vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and heart arrhythmias. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and other soft tissue repairs, in addition to hemostats and surgical sealants.

Officers and directors

Timothy M. Ring Chairman of the Board, Chief Executive Officer
Age: 57
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John H. Weiland President, Chief Operating Officer, Director
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jim C. Beasley Group President
Age: 51
Bio & Compensation  - Reuters
Timothy P. Collins Group President
Age: 54
Bio & Compensation  - Reuters
Christopher S. Holland Chief Financial Officer, Senior Vice President
Age: 48
Bio & Compensation  - Reuters
Samrat S. Khichi Senior Vice President, General Counsel, Secretary
Age: 47
Bio & Compensation  - Reuters
John A. DeFord Ph.D. Senior Vice President - Science, Technology and Clinical Affairs
Age: 53
Bio & Compensation  - Reuters
Frank Lupisella Jr. Vice President, Controller
Age: 54
Bio & Compensation  - Reuters
Sharon M. Alterio Group Vice President
Age: 52
Bio & Compensation  - Reuters
Patricia G. Christian Vice President - Quality, Regulatory and Medical Affairs
Age: 54
Bio & Compensation  - Reuters